Third Rock Ventures said today it has named Robert Kamen, previously of Oxford Bioscience Partners, as an entrepreneur-in-residence. Kamen’s 30 years in biologics includes time spent as president of Abbott Bioresearch Center, where was involved in the discovery of the blockbuster rheumatoid arthritis drug adalimumab (Humira), according to Third Rock. Kamen is also an alumnus of the legendary Genetics Institute, where he began his successful career. Third Rock said that Kamen, who will be based in the firm’s Boston office, is expected take part in the development of potential new companies.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
